Published in EMBO J on July 08, 2011
Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med (2015) 1.29
The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution. Front Mol Neurosci (2014) 1.10
Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med (2015) 1.07
Prions and the potential transmissibility of protein misfolding diseases. Annu Rev Microbiol (2013) 1.04
cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc Natl Acad Sci U S A (2015) 0.93
The proteasome and the degradation of oxidized proteins: Part I-structure of proteasomes. Redox Biol (2013) 0.92
Dendritic spinopathy in transgenic mice expressing ALS/dementia-linked mutant UBQLN2. Proc Natl Acad Sci U S A (2014) 0.91
Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1. Elife (2016) 0.89
Ubiquitin-specific protease 14 modulates degradation of cellular prion protein. Sci Rep (2015) 0.87
Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome. Elife (2015) 0.86
De novo prion aggregates trigger autophagy in skeletal muscle. J Virol (2013) 0.86
Increased expression of p62/SQSTM1 in prion diseases and its association with pathogenic prion protein. Sci Rep (2014) 0.85
Dysfunction in protein clearance by the proteasome: impact on autoinflammatory diseases. Semin Immunopathol (2015) 0.84
Misfolded PrP and a novel mechanism of proteasome inhibition. Prion (2012) 0.83
Gene expression profiling of mesenteric lymph nodes from sheep with natural scrapie. BMC Genomics (2014) 0.79
N-terminal domain of prion protein directs its oligomeric association. J Biol Chem (2014) 0.78
Prion degradation pathways: Potential for therapeutic intervention. Mol Cell Neurosci (2015) 0.78
Ubiquitin ligase gp78 targets unglycosylated prion protein PrP for ubiquitylation and degradation. PLoS One (2014) 0.78
Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin-proteasome system. Acta Neuropathol (2015) 0.77
Cytosolic PrP can participate in prion-mediated toxicity. J Virol (2014) 0.77
The Logic of the 26S Proteasome. Cell (2017) 0.76
Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia. Ageing Res Rev (2016) 0.75
Tau toxicity feeds forward in frontotemporal dementia. Nat Med (2016) 0.75
Proteasome impairment in neural cells derived from HMSN-P patient iPSCs. Mol Brain (2017) 0.75
Metabolism of minor isoforms of prion proteins: Cytosolic prion protein and transmembrane prion protein. Neural Regen Res (2013) 0.75
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Prions. Proc Natl Acad Sci U S A (1998) 27.80
Novel proteinaceous infectious particles cause scrapie. Science (1982) 24.09
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev (2002) 16.10
The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell (1994) 11.62
Mice devoid of PrP are resistant to scrapie. Cell (1993) 11.46
Protein degradation and protection against misfolded or damaged proteins. Nature (2003) 10.19
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 9.79
The roles of intracellular protein-degradation pathways in neurodegeneration. Nature (2006) 9.77
The ubiquitin-proteasome proteolytic pathway. Cell (1994) 9.75
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell (1994) 8.90
Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci (2003) 8.44
A general model of prion strains and their pathogenicity. Science (2007) 6.94
A gated channel into the proteasome core particle. Nat Struct Biol (2000) 5.42
Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol (2004) 5.14
Proteasome inhibitors: from research tools to drug candidates. Chem Biol (2001) 5.06
Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's alpha ring opens the gate for substrate entry. Mol Cell (2007) 4.54
Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases. Mol Cell (2008) 3.49
Structural basis for the activation of 20S proteasomes by 11S regulators. Nature (2000) 3.04
Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ (2006) 3.04
Pathway complexity of prion protein assembly into amyloid. J Biol Chem (2002) 2.96
The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release. Mol Cell (2001) 2.91
ATP binding to PAN or the 26S ATPases causes association with the 20S proteasome, gate opening, and translocation of unfolded proteins. Mol Cell (2005) 2.82
The 1.9 A structure of a proteasome-11S activator complex and implications for proteasome-PAN/PA700 interactions. Mol Cell (2005) 2.68
Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (1995) 2.61
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem (2006) 2.59
Prions and their partners in crime. Nature (2006) 2.55
Species-barrier-independent prion replication in apparently resistant species. Proc Natl Acad Sci U S A (2000) 2.50
The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem (1999) 2.29
Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J (2002) 2.26
Ubiquitinated proteins activate the proteasome by binding to Usp14/Ubp6, which causes 20S gate opening. Mol Cell (2009) 2.10
Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell (2007) 2.01
A transgenic mouse model of the ubiquitin/proteasome system. Nat Biotechnol (2003) 1.95
Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science (1999) 1.95
Differential roles of the COOH termini of AAA subunits of PA700 (19 S regulator) in asymmetric assembly and activation of the 26 S proteasome. J Biol Chem (2008) 1.93
Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci (2008) 1.79
Isolation of mammalian 26S proteasomes and p97/VCP complexes using the ubiquitin-like domain from HHR23B reveals novel proteasome-associated proteins. Biochemistry (2009) 1.78
Interactions of PAN's C-termini with archaeal 20S proteasome and implications for the eukaryotic proteasome-ATPase interactions. EMBO J (2009) 1.60
Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging (2007) 1.58
Proteasome disassembly and downregulation is correlated with viability during stationary phase. Curr Biol (2003) 1.44
Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis. J Biol Chem (2005) 1.42
Molecular distinction between pathogenic and infectious properties of the prion protein. J Virol (2003) 1.38
Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20 S proteasomes. Evidence for peptide-induced channel opening in the alpha-rings. J Biol Chem (2002) 1.32
Polyubiquitin substrates allosterically activate their own degradation by the 26S proteasome. Nat Struct Mol Biol (2009) 1.30
Multiple folding pathways for heterologously expressed human prion protein. Biochim Biophys Acta (1999) 1.29
Formation of critical oligomers is a key event during conformational transition of recombinant syrian hamster prion protein. J Biol Chem (2003) 1.29
Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J Biol Chem (1995) 1.28
HECTD2 is associated with susceptibility to mouse and human prion disease. PLoS Genet (2009) 1.18
Binding of amyloid beta protein to the 20 S proteasome. J Biol Chem (1997) 1.15
Variably modulated gating of the 26S proteasome by ATP and polyubiquitin. Biochem J (2009) 1.12
A tetrahedral transition state at the active sites of the 20S proteasome is coupled to opening of the alpha-ring channel. Structure (2009) 1.11
Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. J Neurosci (2010) 1.10
Oligomerization of the human prion protein proceeds via a molten globule intermediate. J Biol Chem (2007) 1.04
Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. J Pathol (2004) 1.01
Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie (2008) 0.96
Expression of mutant or cytosolic PrP in transgenic mice and cells is not associated with endoplasmic reticulum stress or proteasome dysfunction. PLoS One (2011) 0.96
Molecular basis of cerebral neurodegeneration in prion diseases. FEBS J (2007) 0.90
Formation of soluble oligomers and amyloid fibrils with physical properties of the scrapie isoform of the prion protein from the C-terminal domain of recombinant murine prion protein mPrP-(121-231). J Biol Chem (2006) 0.85
Prions and the proteasome. Biochim Biophys Acta (2008) 0.84
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell (2004) 11.33
Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA (2002) 9.87
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab (2007) 8.90
FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab (2007) 8.05
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J (2004) 7.02
A controlled trial of inpatient and outpatient geriatric evaluation and management. N Engl J Med (2002) 6.37
PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A (2006) 5.28
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell (2010) 5.23
Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol (2011) 4.98
Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science (2003) 4.57
Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's alpha ring opens the gate for substrate entry. Mol Cell (2007) 4.54
Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet (2005) 4.21
Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol (2006) 4.01
Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages. J Biol Chem (2007) 3.68
Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science (2003) 3.59
Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases. Mol Cell (2008) 3.49
The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol (2002) 3.45
Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J (2006) 3.27
An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol (2002) 3.22
PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell (2009) 3.17
ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Mol Cell (2003) 3.14
Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet (2006) 3.12
During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol (2009) 3.03
BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J (2002) 2.98
Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell (2004) 2.89
International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev (2002) 2.86
IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab (2004) 2.82
Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science (2004) 2.82
ATP binding to PAN or the 26S ATPases causes association with the 20S proteasome, gate opening, and translocation of unfolded proteins. Mol Cell (2005) 2.82
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med (2008) 2.78
Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature (2011) 2.74
Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain (2012) 2.65
Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet (2011) 2.60
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem (2006) 2.59
Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron (2007) 2.58
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol (2005) 2.49
The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism. Proc Natl Acad Sci U S A (2005) 2.47
The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem (2005) 2.44
MPN+, a putative catalytic motif found in a subset of MPN domain proteins from eukaryotes and prokaryotes, is critical for Rpn11 function. BMC Biochem (2002) 2.43
Autoantibodies in sporadic Creutzfeldt-Jakob disease. JAMA Neurol (2013) 2.42
Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain (2003) 2.42
hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37. EMBO J (2006) 2.35
PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS One (2008) 2.33
Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature (2003) 2.31
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Patterns of gene expression in atrophying skeletal muscles: response to food deprivation. FASEB J (2002) 2.29
ATP binds to proteasomal ATPases in pairs with distinct functional effects, implying an ordered reaction cycle. Cell (2011) 2.27
A systematic review of prion therapeutics in experimental models. Brain (2006) 2.25
Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol (2002) 2.17
A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain (2008) 2.13
Extraproteasomal Rpn10 restricts access of the polyubiquitin-binding protein Dsk2 to proteasome. Mol Cell (2008) 2.12
Ubiquitinated proteins activate the proteasome by binding to Usp14/Ubp6, which causes 20S gate opening. Mol Cell (2009) 2.10
Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet (2013) 2.09
A stress-responsive system for mitochondrial protein degradation. Mol Cell (2010) 2.05
Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell (2007) 2.01
Analysis of 2000 consecutive UK tonsillectomy specimens for disease-related prion protein. Lancet (2004) 1.96
Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. Nat Commun (2011) 1.96
Cancer vulnerabilities unveiled by genomic loss. Cell (2012) 1.95
Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol (2009) 1.94
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci (2010) 1.92
Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab (2010) 1.90
Trehalose synthesis is induced upon exposure of Escherichia coli to cold and is essential for viability at low temperatures. Proc Natl Acad Sci U S A (2002) 1.85
Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc Natl Acad Sci U S A (2011) 1.85
Variant CJD in an individual heterozygous for PRNP codon 129. Lancet (2009) 1.84
Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol (2004) 1.83
TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J (2003) 1.83
The central unit within the 19S regulatory particle of the proteasome. Nat Struct Mol Biol (2008) 1.82
Complementary roles for Rpn11 and Ubp6 in deubiquitination and proteolysis by the proteasome. J Biol Chem (2003) 1.80
The ACTIVE cognitive training trial and health-related quality of life: protection that lasts for 5 years. J Gerontol A Biol Sci Med Sci (2006) 1.79
The structure of the 26S proteasome subunit Rpn2 reveals its PC repeat domain as a closed toroid of two concentric α-helical rings. Structure (2012) 1.78
Isolation of mammalian 26S proteasomes and p97/VCP complexes using the ubiquitin-like domain from HHR23B reveals novel proteasome-associated proteins. Biochemistry (2009) 1.78
Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin. Biochem J (2008) 1.77
Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell (2013) 1.74
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest (2015) 1.74
Heat shock and oxygen radicals stimulate ubiquitin-dependent degradation mainly of newly synthesized proteins. J Cell Biol (2008) 1.71
Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci U S A (2008) 1.71
A novel prion disease associated with diarrhea and autonomic neuropathy. N Engl J Med (2013) 1.69
The effects of the ACTIVE cognitive training trial on clinically relevant declines in health-related quality of life. J Gerontol B Psychol Sci Soc Sci (2006) 1.69
ATP-dependent steps in the binding of ubiquitin conjugates to the 26S proteasome that commit to degradation. Mol Cell (2010) 1.68
Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. EMBO J (2002) 1.68
BMP signaling controls muscle mass. Nat Genet (2013) 1.68
Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3. Proc Natl Acad Sci U S A (2002) 1.68
Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J Biol Chem (2010) 1.66
Ubiquitin-proteasome-dependent degradation of a mitofusin, a critical regulator of mitochondrial fusion. Mol Biol Cell (2008) 1.66
Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett (2010) 1.65
Rates and predictors of 30-day readmission among commercially insured and Medicaid-enrolled patients hospitalized with systolic heart failure. Circ Heart Fail (2012) 1.62
Interactions of PAN's C-termini with archaeal 20S proteasome and implications for the eukaryotic proteasome-ATPase interactions. EMBO J (2009) 1.60
Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. PLoS Pathog (2012) 1.60